Epoetin beta for the treatment of chemotherapy-induced anemia: an update

被引：6

作者：

Galli, Luca ^{[1
]}

Ricci, Clara ^{[2
]}

Egan, Colin Gerard ^{[2
]}

机构：

[1] Univ Hosp Pisa, Oncol Unit 2, Pisa, Italy

[2] Primula Multimedia SRL, Pisa, Italy

来源：

ONCOTARGETS AND THERAPY | 2015年 / 8卷

关键词：

epoetin beta; erythropoietin; chemotherapy; cancer; anemia; treatment; RECOMBINANT-HUMAN-ERYTHROPOIETIN; METASTATIC COLORECTAL-CANCER; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; PHASE-III TRIAL; PATIENTS RECEIVING CHEMOTHERAPY; SQUAMOUS-CELL CARCINOMA; DARBEPOETIN ALPHA; BREAST-CANCER; DOUBLE-BLIND;

D O I：

10.2147/OTT.S77497

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient's quality of life, should be treated when first diagnosed. Initial trials with ESAs have shown efficacy in improving quality of life and reducing the need for blood transfusions in patients with chemotherapy-induced anemia. However, recent meta-analyses have provided conflicting data on the impact of ESAs on survival and tumor progression. Here we provide an overview of these recent data and review the role of epoetin beta in the treatment of chemotherapy-induced anemia over the past 20 years.

引用

页码：583 / 591

页数：9

共 50 条

[1] Efficacy of Weekly Epoetin Beta in the Treatment of Chemotherapy-Induced Anemia in Solid Tumors.
Oudard, Stephane
Quoix, Elisabeth
Jenabian, Arash
Bergougnoux, Loic
Chouahnia, Kader
Ferrero, Jean-Marc
Misset, Jean-Louis
Spaeth, Dominique
[J]. THERAPIE, 2009, 64 (01): : 17 - 25
[2] Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients with chemotherapy-induced anemia
Fujisaka, Y
Tamura, T
Ohe, K
Kunitoh, H
Sekine, I
Yamamoto, N
Nokihara, H
Horiike, A
Kodama, T
Saijo, N
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 780S - 780S
[3] Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained
Aapro, Matti
Krendyukov, Andriy
Schiestl, Martin
Gascon, Pere
[J]. BIODRUGS, 2018, 32 (02) : 129 - 135
[4] Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Herrington, JD
Davidson, SL
Tomita, DK
Green, L
Smith, RE
Boccia, RV
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (01) : 54 - 62
[5] Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
Kurtz, Jean-Emmanuel
Soubeyran, Pierre
Michallet, Mauricette
Luporsi, Elisabeth
Albrand, Helene
[J]. ONCOTARGETS AND THERAPY, 2016, 9 : 6689 - 6693
[6] Effectiveness Of Biosimilar Epoetin Alfa For The Treatment Of Chemotherapy-Induced Anemia In Patients With Hematological Malignancies
Agrawal, Samir G.
Guy, Andrea
O'Flaherty, Patricia
Turner, Matthew
[J]. BLOOD, 2013, 122 (21)
[7] Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
Matti Aapro
Andriy Krendyukov
Martin Schiestl
Pere Gascón
[J]. BioDrugs, 2018, 32 : 137 - 138
[8] Epoetin beta once weekly:: review of its efficacy and safety in patients with chemotherapy-induced anemia
Spaeth, Dominique
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (06) : 875 - 885
[9] DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA: A HEALTH ECONOMIC EVALUATION
Finek, J.
Holubec, L.
Wiesnerova, A.
Pav, Z.
Dusek, V.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 344 - 344
[10] DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA: A HEALTH ECONOMIC EVALUATION
Finek, J.
Holubec, L.
Wiesnerova, A.
Pav, Z.
Dusek, L.
[J]. TUMOR BIOLOGY, 2010, 31 : S102 - S103

← 1 2 3 4 5 →